Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Mar Drugs ; 17(9)2019 Sep 05.
Article in English | MEDLINE | ID: mdl-31491907

ABSTRACT

There is a variety of antineoplastic drugs that are based on natural compounds from ecological niches with high evolutionary pressure. We used two cell lines (Jurkat J16 and Ramos) in a screening to assess 300 different naturally occurring compounds with regard to their antineoplastic activity. The results of the compounds 4,6-dibromo-2-(2',4'-dibromophenoxy)phenol (P01F03), 4,5,6-tribromo-2-(2',4'-dibromophenoxy)phenol (P01F08), and 5-epi-nakijinone Q (P03F03) prompted us to perform further research. Using viability and apoptosis assays on the cell lines of primary human leukemic and normal hematopoietic cells, we found that P01F08 induced apoptosis in the cell lines at IC50 values between 1.61 and 2.95 µM after 72 h. IC50 values of peripheral blood mononuclear cells (PBMNCs) from healthy donors were higher, demonstrating that the cytotoxicity in the cell lines reached 50%, while normal PBMNCs were hardly affected. The colony-forming unit assay showed that the hematopoietic progenitor cells were not significantly affected in their growth by P01F08 at a concentration of 3 µM. P01F08 showed a 3.2-fold lower IC50 value in primary leukemic cells [acute myeloid leukemia (AML)] compared to the PBMNC of healthy donors. We could confirm the antineoplastic effect of 5-epi-nakijinone Q (P03F03) on the cell lines via the induction of apoptosis but noted a similarly strong cytotoxic effect on normal PBMNCs.


Subject(s)
Antineoplastic Agents/therapeutic use , Phenol/therapeutic use , Adult , Aged , Apoptosis/drug effects , Cell Line, Tumor , Female , HL-60 Cells , Hematopoietic Stem Cells/drug effects , Humans , Jurkat Cells , Leukemia, Myeloid, Acute/drug therapy , Leukocytes, Mononuclear/drug effects , Male , Middle Aged , THP-1 Cells
2.
Blood ; 123(4): 520-9, 2014 Jan 23.
Article in English | MEDLINE | ID: mdl-24169825

ABSTRACT

Janus kinases (Jak) play essential roles in cytokine and growth factor signaling. Conventional gene targeting of Jak2, creating a null allele, leads to a block in definitive erythropoiesis as a result of failing signal transduction at the homomeric erythropoietin receptor (EpoR) and at the heteromeric interferon γ receptor (IFNGR). To investigate the in vivo relevance of the activation loop of Jak2, a Jak2-YY1007/1008FF knockin mutation was introduced into the germline of mice. The phenotype of the Jak2(FF/FF) mouse line reveals that tyrosine residues 1007/1008 are absolutely essential for kinase function and signal transduction at the homomeric EpoR. Detailed studies using the Jak2 activation loop mutant uncover an essential scaffolding function of Jak2 within the IFNGR receptor complex and reveal that Jak1 can mediate a semi-redundant function for IFNGR signal transduction. These studies are highly important for the molecular understanding of cytokine and growth factor signaling and provide new insights for future strategies in the design of pharmacological blockers of Jak2.


Subject(s)
Janus Kinase 2/metabolism , Mutation , Signal Transduction , Alleles , Animals , Cells, Cultured , Fibroblasts/metabolism , Janus Kinase 1/metabolism , Mice , Mice, Transgenic , Phenotype , Phosphorylation , Receptors, Erythropoietin/metabolism , Receptors, Interferon/metabolism , Tyrosine/metabolism , Interferon gamma Receptor
SELECTION OF CITATIONS
SEARCH DETAIL